Timothy Deer, MD
Interventional Pain Medicine · Charleston, WVNPI 1861424210
Payments from drug & device makers
What this record shows
The money is spread across several categories — ownership interests (48.6%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Boston Scientific at 48.1% of the total. Reporting peaked in 2019 at $1,834,084 and has fallen 88.4% since, to $212,507 in 2025.
Across 2,477 payments — averaging $1379.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1.6M
- Abbott$1.2M
- Saluda Medical Americas, Inc.$217K
- Spinal Simplicity, LLC$111K
- Vertos Medical, Inc.$93K
- Painteq LLC$37K
- plus $105K from 27 others
Across 281 payments — averaging $2488.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$239K
- Avanos Medical$183K
- SPR Therapeutics, Inc$125K
- Boston Scientific$47K
- Saluda Medical Americas, Inc.$47K
- Vertiflex, Inc.$19K
- plus $39K from 5 others
Across 11 payments — averaging $7897.44 each. An ownership or investment interest held by the physician or an immediate family member.
- SPR Therapeutics, Inc$70K
- Spinal Simplicity, LLC$17K
- Foundation Fusion Solutions, LLC$0
What the payments were for
- Royalty or licence$4890%
- Consulting fees$1,074,71431%
- Speaking & faculty fees$460,43313%
- Travel & lodging$137,3744%
- Food & beverage$75,2222%
- Education$5,0000%
- Entertainment$820%
- Ownership interest$1,661,78149%
- Other$2,4680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 44 | $1,643,714 |
| Abbott | 1,869 | $1,211,180 |
| Saluda Medical Americas, Inc. | 146 | $216,821 |
| Spinal Simplicity, LLC | 75 | $111,288 |
| Vertos Medical, Inc. | 63 | $92,688 |
| Painteq LLC | 85 | $36,923 |
| Nalu Medical, Inc. | 17 | $26,575 |
| Vertiflex, Inc. | 18 | $17,807 |
| Medtronic(2 entities) | 27 | $14,709 |
| Biotronik NRO, Inc. | 10 | $8,815 |
| SPR Therapeutics, Inc | 26 | $6,179 |
| Nevro Corp. | 17 | $6,019 |
| Flowonix Medical Incorporated | 2 | $5,803 |
| Ferring Pharmaceuticals Inc. | 5 | $5,595 |
| Foundation Fusion Solutions, LLC | 12 | $4,477 |
| MML US, Inc. | 12 | $3,742 |
| Stryker | 9 | $1,902 |
| Si-bone, Inc. | 11 | $565 |
| Biogen | 1 | $554 |
| Aurora Spine, Inc. | 1 | $489 |
| Relievant Medsystems, Inc. | 6 | $363 |
| Averitas Pharma Inc. | 4 | $246 |
| Curonix LLC | 5 | $231 |
| Mesoblast, Inc. | 1 | $178 |
| Globus Medical | 2 | $125 |
| Tenon Medical, Inc. | 1 | $110 |
| Neuroone Medical Technologies Corporation | 1 | $107 |
| Axonics, Inc. | 1 | $76 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $74 |
| Stimwave Technologies Incorporated | 1 | $68 |
| Stratus Medical, LLC | 1 | $64 |
| Johnson & Johnson | 2 | $56 |
| Avanos Medical | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$1,629,025
- PROCLAIM$461,983
- Neuromodulation Dspsbls and Accs$348,212
- Evoke$126,451
- Proclaim Family of SCS IPGs$121,776
- HA MINUTEMAN G3-R$109,267
- mild Device Kit$94,281
- IonicRF Generator$65,920
- Proclaim DRG IPG$56,259
- Proclaim IPG$53,781
- Evoke study$46,759
- Evoke SCS$40,950
- PAINTEQ$35,141
- Prodigy Family of SCS IPGs$29,083
- Nalu Neurostimulation System$26,501
- Axium INS DRG IPG$26,248
- Superion ISS$17,754
- INTELLIS$10,631
- Prometra II$5,803
- SPRINT PNS System$5,471
How this compares
Too few interventional pain medicine providers in West Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 224 | $2,467 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 135 | $1,633 |
| Cephalexin | 136 | $644 |
| Gabapentin | 33 | $428 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 20 | $424 |
| Hydromorphone Hcl | 19 | $201 |
| Clindamycin Hcl | 30 | $109 |
| Tramadol Hcl | 28 | $101 |
| Tizanidine Hcl | 13 | $84 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Charleston
- Christopher KimCharleston$108K
- Anuj ShahCharleston$7K
- Rudy MalayilHuntington$104K
- Andrew ThymiusBeckley$9K
- Raymond GreaserWheeling$9K
- Stephanie leWeirton$9K
- Corinne Layne StuartBridgeport$8K
- Luay MradParkersburg$8K
- George van OstenMartinsburg$145
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.